Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1269.80
-78.90 (-5.85%)
< Home < Back

Dr. Reddy’s Laboratories gains on signing commercialization deal with Hatchtech

Date: 14-09-2015

Dr. Reddys Laboratories is currently trading at Rs 4011.00, up by 5.75 points or 0.14% from its previous closing of Rs 4005.25 on the BSE.

The scrip opened at Rs. 4010.00 and has touched a high and low of Rs. 4019.25 and Rs. 3999.05 respectively. So far 1576 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4337.00 on 14-Aug-2015 and a 52 week low of Rs. 2883.40 on 17-Oct-2014.

Last one week high and low of the scrip stood at Rs. 4095.60 and Rs. 3856.00 respectively. The current market cap of the company is Rs. 68342.02 crore.

The promoters holding in the company stood at 25.48% while Institutions and Non-Institutions held 43.67% and 13.81% respectively.

Dr. Reddy's Laboratories has signed a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

Additionally, Hatchtech will be filing its New Drug Application for Xeglyzew with the US Food and Drug Administration (FDA). If approved, the product will be marketed in the United States by Promius Pharma, a wholly-owned specialty company of Dr. Reddy's Laboratories. As part of the agreement Dr. Reddy's will pay Hatchtech an upfront amount of $10MM, up to $ 50 million based on pre commercialization milestones and an undisclosed amount based on post commercialization milestones, linked to achievement of annual net sales targets.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.